The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Merck Sharp & Dohme
Pembrolizumab for previously treated advanced anal squamous cell carcinoma: Pooled results from the KEYNOTE-028 and KEYNOTE-158 studies.
 
Aurelien Marabelle
Stock and Other Ownership Interests - PEGASCY
Honoraria - AstraZeneca/MedImmune; Bristol-Myers Squibb; Merieux Nutrisciences; Oncovir
Consulting or Advisory Role - AMGEN; AstraZeneca; Bayer; Bioncotech; Boehringer Ingelheim; CERENIS THERAPEUTICS; Eisai; Gritstone Bio; ImCheck therapeutics; Innate Pharma; Lytix Biopharma; Merck Serono; Molecular Partners; MSD; NOVARTIS; OSE Immunotherapeutics; Partner Therapeutics; Pfizer; Pfizer; Pierre Fabre; Redx Pharma; Roche; Sanofi; SERVIER; Sotio; Symphogen
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; MSD; Roche
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); MERUS (Inst); MSD (Inst); Transgene (Inst)
Patents, Royalties, Other Intellectual Property - monoclonal antibodies against CD81 (Stanford University)
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; MSD; Roche
Other Relationship - PEGASCY
 
Philippe Alexandre Cassier
Honoraria - Amgen; AstraZeneca; Blueprint Medicines; Novartis; Roche/Genentech
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Bayer (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); GlaxoSmithKline (Inst); Innate Pharma (Inst); Janssen (Inst); Lilly (Inst); Loxo (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Plexxikon (Inst); Roche/Genentech (Inst); Taiho Pharmaceutical (Inst); Toray Industries (Inst); Transgene (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Merck Sharp & Dohme; Netris Pharma; Novartis; Roche
 
Marwan Fakih
Consulting or Advisory Role - Amgen; Array BioPharma; Genentech/Roche
Speakers' Bureau - Amgen; Taiho Pharmaceutical
Research Funding - Amgen (Inst); AstraZeneca (Inst); Novartis (Inst)
 
Steven Chuan-Hao Kao
Honoraria - AstraZeneca; Bristol-Myers Squibb; MSD Oncology; Pfizer; Roche
Consulting or Advisory Role - Boehringer Ingelheim (Inst); MSD Oncology (Inst); Pfizer (Inst)
Research Funding - AstraZeneca (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Roche
 
Dorte Nielsen
No Relationships to Disclose
 
Antoine Italiano
Honoraria - Bayer; Daiichi Sankyo; Epizyme; IPSEN; Lilly; Novartis; Roche
Consulting or Advisory Role - Bayer; Daiichi Sankyo; Epizyme; Immune Design; Lilly; Roche
Research Funding - AstraZeneca/MedImmune; Bayer; Merck Serono; Merck Serono; MSD Oncology; PharmaMar; Roche
Patents, Royalties, Other Intellectual Property - Bristol-Myers Squibb
 
Tormod Guren
No Relationships to Disclose
 
Marloes Van Dongen
Research Funding - Netherlands Cancer Institute (Inst)
 
Kristen Renee Spencer
No Relationships to Disclose
 
Giovanni M. Bariani
Consulting or Advisory Role - Libbs
Research Funding - Bristol-Myers Squibb; Mabxience; Merck Sharp & Dohme
 
Paolo Antonio Ascierto
Stock and Other Ownership Interests - PrimeVax
Consulting or Advisory Role - 4SC; Alkermes; Amgen; Array BioPharma; AstraZeneca; Bristol-Myers Squibb; Genmab; Idera; Immunocore; Incyte; Italfarmaco; MedImmune; Merck Serono; Merck Sharp & Dohme; Nektar; Newlink Genetics; Novartis; Pierre Fabre; Roche/Genentech; Sandoz; Sanofi; Sun Pharma; Syndax; Ultimovacs
Research Funding - Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Merck Sharp & Dohme
 
Armando Santoro
Consulting or Advisory Role - ARQULE; Bayer; Bristol-Myers Squibb; Eisai; Gilead Sciences; MSD; Pfizer; Sanofi; SERVIER
Speakers' Bureau - Abbvie; Amgen; ArQule; AstraZeneca; Bayer; Bristol-Myers Squibb; Celgene; Eisai; Gilead Sciences; Lilly; MSD; Novartis; Pfizer; Roche; Sandoz; Servier; Takeda
 
Sandrine Hiret
Consulting or Advisory Role - AstraZeneca; Roche
 
Patrick Alexander Ott
Consulting or Advisory Role - Array BioPharma; Bristol-Myers Squibb; Celldex; CytomX Therapeutics; Genentech; Merck; Novartis; Pfizer
Research Funding - ARMO BioSciences (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Celldex (Inst); CytomX Therapeutics (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Merck (Inst); Neon Therapeutics (Inst); Pfizer (Inst)
Expert Testimony - Boehringer Ingelheim
 
Sarina Anne Piha-Paul
Consulting or Advisory Role - Merck
Research Funding - Abbvie (Inst); Alkermes (Inst); Aminex (Inst); Amphivena Therapetics, Inc. (Inst); Biomarin (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Cerulean Pharma (Inst); Chugai Pharma (Inst); Curis (Inst); Daiichi Sankyo (Inst); Five Prime Therapeutics (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Helix BioPharma (Inst); Incyte (Inst); Jacobio (Inst); Lilly (Inst); MedImmune (Inst); Medivation (Inst); Merck Sharp and Dohme Corp. (Inst); New Link Genetics/BlueLink Pharmaceuticals (Inst); Novartis (Inst); Pfizer (Inst); Pieris Pharmaceuticals (Inst); Principa Biopharma (Inst); Puma Biotechnology (Inst); RAPT Therapeutics (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Tesaro (Inst); TransThera Biosciences (Inst); XuanZhu (Inst)
 
Chih-Chin Liu
Employment - Merck Sharp & Dohme
 
Melanie A. Leiby
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Kevin Norwood
No Relationships to Disclose
 
Jean-Pierre Delord
Consulting or Advisory Role - Bristol-Myers Squibb; MSD Oncology; Novartis; Roche/Genentech
Research Funding - Bristol-Myers Squibb (Inst); Genentech (Inst); MSD Oncology (Inst)